CELLMED 2023 KCI Impact Factor : 0.03
-
pISSN : 3022-6805 / eISSN : 3022-6791
- https://journal.kci.go.kr/cellmed
KJCKorea
Journal Central
Analysis of therapeutic targets for COVID 19-nCoV/SARS-CoV-2 and discovery by virtual screening methods
- CELLMED
- Abbr : CellMed
- 2020, 10(2), pp.14-14
- DOI : 10.5667/CellMed.2020.0014
- Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
- Research Area : Medicine and Pharmacy > General Medicine
- Received : March 29, 2020
- Accepted : April 20, 2020
- Published : May 29, 2020
Sushil Kumar Sharma 1, Ajay Kumar Mishra 2
1Department of Chemistry, Sam Higginbottom University of Agriculture, Technology and Sciences
2MLN Hospital
Withdraw
이 논문은 셀메드세포교정의약학회 윤리위원회(2020.06.15.) 결과 연구부정행위(표절)가 확인되어 게재가 철회된 논문임
ABSTRACT
Experimental drug development is very time consuming, expensive and limited to a relatively small number of targets. However, recent studies show that repositioning of existing drugs can function more efficiently then the novo experimental drug development to minimize cost and risks. Few previous studies have proven that network analysis is a versatile platform for this purpose, as the biological networks are used to model interactions between many different biological concepts. The present study is an attempt to review network based methods in predicting drug targets for drug repositioning. Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the “Complementary Exposure” pattern: the targets of the drugs both hit the HCoV–host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2
KEYWORDS
Statistics
-
356 Viewed
-
65 Downloaded
Tools
Issue List
Citation status
* References for papers published after 2023 are currently being built.
[journal]
Apweiler R
/ 2004
/ UniProt : the Universal Protein knowledgebase
/ Nucleic Acids Res
32
: D115~D119
[journal]
Avorn J.
/ 2015
/ The $2.6 billion pill methodologic and policy considerations
/ N. Engl. J. Med .
372
: 1877~1879
[journal]
Barrows NJ
/ 2016
/ A screen of FDA approved drugs for inhibitors of Zika virus infection
/ Cell Host. Microbe
20
: 259~270
[journal]
Chang CK
/ 2013
/ Transient oligo merization of the SARS CoV N protein implication for virus ribonucleoprotein packaging
/ PLoS ONE
8(3)
: e65045~
[journal]
Chen H
/ 2002
/ Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell
/ J. Virol
76
: 5233~5250
[journal]
Chen N
/ 2020
/ Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descript ive study
/ Lancet
395
: 507~513
[journal]
Chen X
/ 2009
/ Thiopurine analogue inhibitors of severe acute respiratory syndrome coronavirus papain like protease, a deubiquitinating and deISGylating enzyme
/ Antivir. Chem. Chemother
19
: 151~156
[journal]
Cheng F
/ 2018
/ Network based approach to prediction and population based validation of in silico drug repurposing
/ Nat. Commun
9
: 2691~
[journal]
Cheng F
/ 2017
/ Individualized network based drug repositioning infrastructure for precision oncology in the panomics era
/ Brief Bioinformatics
18
: 682~697
[journal]
Cheng F
/ 2019
/ Network based prediction of drug combinations
/ Nat. Commun
10
: 1197~
[journal]
Cheng F
/ 2012
/ Prediction of drug target interactions and drug repositioning via network based inference
/ PLoS Comput. Biol
8
: e1002503~
[journal]
Cheng F
/ 2019
/ A genome wide positioning systems network algorithm for in silico drug repurposing
/ Nat. Commun
10
[journal]
Cheng F
/ 2016
/ Drug repurposing: new treatments for Zika virus infection?
/ Trends Mol. Med
22(919)
: 921~
[journal]
Cheng F
/ 2016
/ Systems biology based investigation of cellular antiviral drug targets identified by gene trap insertional mutagenesis
/ PLoS Comput. Biol
12
: e1005074~
[journal]
Cheng F
/ 2019
/ In silico oncology drug repositioning and polypharmacology
/ Methods Mol. Biol
1878
: 243~261
[journal]
Cheng KW
/ 2015
/ Thiopurine analogs and mycophenolic acid synergistically inhi bit the papain like protease of Middle East respiratory syndrome coronavirus
/ Antivir. Res
115
: 9~16
[journal]
Coordinators NR
/ 2016
/ Database resources of the National Center for Biotechnology Information
/ Nucleic Acids Res
44
: D7~D19
[journal]
de Wilde AH
/ 2014
/ Screening of an FDA approved compound library identifies four small molecule inhibitors of Middle East respiratory syndrome coronavirus replicati on in cell culture
/ Antimicrob. Agents Chemother
58
: 4875~
[journal]
de Wilde AH
/ 2018
/ Host factors in coronavirus replication
/ Curr. Top. Microbiol. Immunol
419
: 1~42
[journal]
de Wit E
/ 2016
/ SARS and MERS: recent insights into emerging coronaviruses
/ Nat. Rev. Microbiol
14
: 523~534
[journal]
Dyall J
/ 2014
/ Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection
/ Antimicrob. Agents Chemother
58
: 4885~4893
[journal]
Dyall J
/ 2017
/ Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies
/ Drugs
77
: 1935~1966
[journal]
Emmott E
/ 2013
/ The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology
/ J. Virol
87
: 9486~9500
[journal]
Erlandson KM
/ 2017
/ The impact of statin and angiotensin converting enzyme inhibitor/angiotensin receptor blocker therapy on cognitive function in adults with human imm unodeficiency virus infection
/ Clin. Infect. Dis
65
: 2042~2049
[journal]
Fang J
/ 2020
/ Network based translation of GWAS findings to pathobiology and drug repurposing for Alzheimer’s disease
/ MedRxiv
60
: 01~51
[journal]
Forni D
/ 2017
/ Molecular evolution of human coronavirus genomes
/ Trends Microbiol
25
: 35~48
[journal]
Garcia CC
/ 2010
/ The development of anti inflammatory drugs for infectious diseases
/ Discov. Med
10
: 479~488
[journal]
Gaulton A
/ 2012
/ ChEMBL: a large scale bioactivity database for drug discovery
/ Nucleic Acids Res
40
: D1100~D1107
[journal]
Greene JA
/ 2017
/ Putting the patient back together social medicine, network medicine, and the limits of reductionism
/ N. Engl. J. Med
377
: 2493~2499
[journal]
He S
/ 2015
/ Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C vi rus infection
/ Sci. Transl. Med
7
: 282~249
[journal]
Hong M
/ 2008
/ Identification of a novel transcriptional repressor(HEPIS)that interacts with nsp 10 of SARS coronavirus
/ Viral Immunol
21
: 153~162
[journal]
Johansen LM
/ 2013
/ FDA approved selective estrogen receptor modulators inhibit Ebola virus infection
/ Med
5
: 190~
[journal]
Josset L
/ 2013
/ Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus
/ mBio
4
: e00165~
[journal]
Karran P
/ 2008
/ Thiopurines in current medical practice:molecular mechanisms and contributions to therapy related cancer
/ Nat. Rev. Cancer
8
: 24~36
[journal]
Kirchdoerfer RN
/ 2019
/ Structure of the SARS CoV nsp12 poly merase bound to nsp7 and nsp8 co factors
/ Nat. Commun
10
: 2342~
[journal]
Ko C
/ 2015
/ The FDA approved drug irbesartan inhibits HBV infection in HepG2 cells stably expressing sodium taurocholate co transporting polypeptide
/ Antivir. Ther
20
: 835~842
[journal]
Lamb J
/ 2006
/ The Conn ectivity Map : using gene expression signatures to connect small molecules, genes, and disease
/ Science
313
: 1929~1935
[journal]
Lasso G
/ 2019
/ A structure informed atlas of human virus interactions
/ Cell
178
: 1526~1541
[journal]
Li F
/ 2005
/ Structure of SARS coronavirus spike receptor binding domain complexed with receptor
/ Science
309
: 1864~1868
[journal]
Li Q
/ 2020
/ Early transmission dynamics in Wuhan, China, of novel coronavirus infected pneumonia
/ N Engl J Med
382
: 1199~
[journal]
Liu C
/ 2020
/ Computational network biology: data, models, and applications
/ Phys. Rep
846
: 01~66
[journal]
Liu TQ
/ 2007
/ BindingDB: a webaccessible database of experimentally determined protein ligand binding affinities
/ Nucleic Acids Res
35
: D198~D201
[journal]
Lu R
/ 2020
/ Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
/ Lancet
395
: 565~574
[journal]
McNulty S
/ 2013
/ Host mTORC1 signaling regulates andes virus replication
/ J. Virol
87
: 912~922
[journal]
Moskowitz DW
/ 2004
/ The central role of angiotensin I converting enzyme in vertebrate pathophysiology
/ Chem
4
: 1433~1454
[journal]
Paules CI
/ 2020
/ Coronavirus infections more than just the common cold
/ JAMA
323
: 707~708
[journal]
Pawson AJ
/ 2014
/ The IUPHAR/BPS Guide to PHARMACOLOGY: an expertdriven knowledgebase of drug targets and their ligands
/ Nucleic Acids Res
42
: D1098~D1106
[journal]
Rainsford KD
/ 2006
/ Influenza (“Bird Flu”), inflammation and anti inflammatory/ analgesic drugs
/ Inflammopharmacology
14
: 2~9
[journal]
Reghunathan R
/ 2005
/ Expression profile of immune response genes in patients with severe acute respiratory syndrome
/ BMC Immunol
6
: 01~11
[journal]
Santos R
/ 2017
/ A comprehensive map of molecular drug targets
/ Nat. Rev. Drug Discov
16
: 19~34
[journal]
Seko Y.
/ 2006
/ Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3
/ Clin. Sci
110
: 379~386
[journal]
Silvestri M
/ 2013
/ Melatonin: its possible role in the management of viral infections a brief review
/ Ital. J. Pediatr
39
: 61~
[journal]
Sirota M
/ 2011
/ Discovery and preclinical validation of drug indications using compendia of public gene expression data
/ Sci. Transl. Med
3
: 96~
[journal]
Smith IN
/ 2019
/ Conformational dynamics and allosteric regulation landscapes of germline PTEN mutations associated with autism compared to those associated with cancer
/ Am. J. Hum. Genet
104
: 861~878
[journal]
Srinivasan V
/ 2012
/ Melatonin in bacterial and viral infections with focus on sepsis: a review
/ Recent Pat. Endocr. Met ab. Immune Drug Discov
6
: 30~39
[journal]
Stöhr S
/ 2016
/ Host cell mTORC1 is required for HCV RNA replication
/ Gut
65
: 2017~2028
[journal]
V'kovski P
/ 2019
/ Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity labeling
/ eLife
8
: e42037~
[journal]
Wang CH
/ 2014
/ Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure
/ Crit. Care Med
42
: 313~321
[journal]
Wang XJ
/ 2015
/ Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepati tis B virus entry by disturbing Na(+) dependent taurocholate cotransporting polypeptide activity
/ Antivir. Res.
120
: 140~146
[journal]
Wrapp D
/ 2020
/ Cryo EM structure of the 2019 nCoV spike in the prefusion conformation
/ Science
03
: 1260~1263
[journal]
Xu M
/ 2016
/ Identification of small molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen
/ Nat. Med
22
: 1101~1107
[journal]
Yang H
/ 2016
/ Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information
/ Nucleic Acids Res
44
: D1069~D1074
[journal]
Yang S
/ 2019
/ Understanding human virus protein protein interactions using a human protein complex based analysis framework
/ mSystems
4
: e00303~
[journal]
Yuan S
/ 2019
/ SREBP dependent lipidomic reprogramming as a broadspectrum antiviral target
/ Commun
10
: 120~
[journal]
Zeng X
/ 2019
/ deepDR : a network based deep learning approach to in silico drug repositioning
/ Bioinformatics
35
: 5191~5198
[journal]
Zeng, X
/ 2020
/ Network based prediction of drug target interactions using an arbitrary order proximity embedded deep forest
/ Bioinformatics
10
: 01~23
[journal]
Zeng, X.
/ 2020
/ Target identification among known drugs by deep learning from heterogeneous networks
/ Chem. Sci
11
: 1775~1797
[journal]
Zhao, Y.
/ 2016
/ Toremifene interacts with and destabilizes the Ebola virus glycoprotein
/ Nature
535
: 169~172
[journal]
Zhou P
/ 2020
/ A pneumonia outbreak associated with a new coronavirus of probable bat origin
/ Nature
579
: 270~273
[journal]
Zumla A
/ 2016
/ Coronaviruses drug discovery and therapeutic options
/ Nat. Rev. Drug Discov
15
: 327~347